Literature DB >> 23418799

Breast cancer screening update.

Maria Tria Tirona1.   

Abstract

Breast cancer is the most common non-skin cancer and the second leading cause of cancer death in North American women. Mammography is the only screening test shown to reduce breast cancer-related mortality. There is general agreement that screening should be offered at least biennially to women 50 to 74 years of age. For women 40 to 49 years of age, the risks and benefits of screening should be discussed, and the decision to perform screening should take into consideration the individual patient risk, values, and comfort level of the patient and physician. Information is lacking about the effectiveness of screening in women 75 years and older. The decision to screen women in this age group should be individualized, keeping the patient's life expectancy, functional status, and goals of care in mind. For women with an estimated lifetime breast cancer risk of more than 20 percent or who have a BRCA mutation, screening should begin at 25 years of age or at the age that is five to 10 years younger than the earliest age that breast cancer was diagnosed in the family. Screening with magnetic resonance imaging may be considered in high-risk women, but its impact on breast cancer mortality is uncertain. Clinical breast examination plus mammography seems to be no more effective than mammography alone at reducing breast cancer mortality. Teaching breast self-examination does not improve mortality and is not recommended; however, women should be aware of any changes in their breasts and report them promptly.

Entities:  

Mesh:

Year:  2013        PMID: 23418799

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  16 in total

1.  Canadian cancer screening disparities: a recent historical perspective.

Authors:  J Kerner; J Liu; K Wang; S Fung; C Landry; G Lockwood; L Zitzelsberger; V Mai
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 2.  Controversies surrounding screening mammography.

Authors:  Pamela M Otto; Christa B Blecher
Journal:  Mo Med       Date:  2014 Sep-Oct

3.  Race Disparities in the Use of Prevention, Screening, and Monitoring Services in Michigan Medicare Beneficiaries With Type 2 Diabetes and Combinations of Multiple Chronic Conditions.

Authors:  John Michael Clements; Brady Thomas West; Batoul Harissa; Nolan Hayden; Mishaal Mustafa Khan; Raghuram Palepu
Journal:  Clin Diabetes       Date:  2020-10

4.  Mammography Screening Practices in Average-Risk Women Aged 40-49 Years in Primary Care: A Comparison of Physician and Nonphysician Providers in Minnesota.

Authors:  Katherine Martin; Rachel I Vogel; Rebekah H Nagler; Jean F Wyman; Nancy Raymond; Deanna Teoh; Alicia M Allen; Kristine M C Talley; Susan Mason; Anne H Blaes
Journal:  J Womens Health (Larchmt)       Date:  2019-07-16       Impact factor: 2.681

5.  Low Awareness of Breast Cancer and Considerable Barriers to Early Presentation Among Saudi Women at a Primary Care Setting.

Authors:  Noura Khamis Al-Khamis
Journal:  J Cancer Educ       Date:  2018-04       Impact factor: 2.037

6.  Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis.

Authors:  Thomas P Ahern; Rulla M Tamimi; Bernard A Rosner; Susan E Hankinson
Journal:  Breast Cancer Res Treat       Date:  2014-02-28       Impact factor: 4.872

7.  The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.

Authors:  Charla C Engels; Nienke A de Glas; Anita Sajet; Esther Bastiaannet; Vincent T H B M Smit; Peter J K Kuppen; Caroline Seynaeve; Cornelis J H van de Velde; Gerrit Jan Liefers
Journal:  Mol Oncol       Date:  2015-10-31       Impact factor: 6.603

8.  The Role of Family Health History in Predicting Midlife Chronic Disease Outcomes.

Authors:  Naomi N Duke; Todd M Jensen; Krista M Perreira; V Joseph Hotz; Kathleen Mullan Harris
Journal:  Am J Prev Med       Date:  2021-07-03       Impact factor: 6.604

9.  No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.

Authors:  S Guedaoura; S Pelletier; W D Foulkes; P Hamet; J Simard; N Wong; Z El Haffaf; J Chiquette; M Dorval
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

10.  Collagen Type XI Alpha 1 Expression in Intraductal Papillomas Predicts Malignant Recurrence.

Authors:  Javier Freire; Lucia García-Berbel; Pilar García-Berbel; Saray Pereda; Ainara Azueta; Pilar García-Arranz; Ana De Juan; Alfonso Vega; Ángela Hens; Ana Enguita; Pedro Muñoz-Cacho; Javier Gómez-Román
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.